|Bid||3.89 x 5200|
|Ask||3.90 x 5200|
|Day's Range||3.86 - 4.03|
|52 Week Range||1.94 - 4.33|
|PE Ratio (TTM)||-5.75|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||5.33|
SOUTH SAN FRANCISCO, Calif. , Oct. 10, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NasdaqGS: RIGL) today announced the closing of its previously announced underwritten public offering of 20,815,000 ...
NEW YORK, NY / ACCESSWIRE / October 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
Rigel Pharmaceuticals (RIGL) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.
SOUTH SAN FRANCISCO, Calif. , Oct. 4, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NasdaqGS: RIGL), today announced the pricing of its previously announced underwritten public offering of 18,100,000 ...
SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that it intends to offer and sell up to $40,000,000 of shares of its common stock in an underwritten public offering. Rigel expects to grant the underwriters a 30-day option to purchase up to an additional $6,000,000 of shares of common stock sold in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
NEW YORK, NY / ACCESSWIRE / October 3, 2017 / Shares of Catabasis surged on Monday after announcing this past Friday that it would be presenting data on its investigational oral small molecule Edasalonexent ...
Rigel Pharmaceuticals Inc. said Tuesday a phase 2 study of a treatment for patients with warm antibody autoimmune hemolytic anemia, or AIHA, met its main goal in stage 1 of the trial, sending its stock ...
SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that the company recently completed enrollment of Stage 1 of its Phase 2, open-label, multi-center, two-stage study of its investigational drug fostamatinib for the treatment of patients with warm antibody AIHA. On a top-line, preliminary basis, the Phase 2 study has achieved the pre-specified primary efficacy endpoint for Stage 1. This Phase 2 study, also known as the SOAR study, is evaluating the safety and efficacy of fostamatinib in patients with warm antibody AIHA who have previously received at least one treatment for this disease, but did not have a meaningful benefit and are still anemic.
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that during the company's mid-cycle meeting with the U.S. Food and Drug Administration (FDA) the FDA indicated that, at this point, it is not planning to hold an Oncology Drugs Advisory Committee (ODAC) meeting to discuss the New Drug Application (NDA) for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). Additionally, the FDA indicated that it anticipates meeting the Prescription Drug User Fee Act (PDUFA) action date for the application review, which is April 17, 2018. In an earlier communication, the FDA had conditionally approved the proprietary name TavalisseTM.